HSR21-070: Feasibility of Tracking Digital Activity, Sleep, and Patient-Reported Outcomes (PROs) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Undergoing an In-Class Transition From Parenteral Bortezomib-Based Therapy to Oral Ixazomib-Lenalidomide-Dexamethasone (IRd) in the Ongoing Community-Based United States (US) MM-6 Study (NCT03173092)

Authors: Kirsten Stuber MSN, MBA, FNP-BC, AOCNP1, Habte A. Yimer MD1, Karin Choquette MSN, AGNP-C, CCRC2, Sudhir Manda MD, FACP2, Jennifer Clayton MSN, ACNP3, Saulius Girnius MD3, Joshua Richter MD4, Presley Whidden MS5, Kimberly Bogard PharmD, BCPS5, Dasha Cherepanov PhD5, and Stephen J. Noga MD, PhD5
View More View Less
  • 1 Texas Oncology - Tyler/US Oncology Research, Tyler, TX
  • | 2 Arizona Oncology, Tucson, AZ
  • | 3 Trihealth Cancer Institute, Cincinnati, OH
  • | 4 Tisch Cancer Institute: Icahn School of Medicine at Mount Sinai, New York, NY
  • | 5 Millennium Pharmaceuticals, Inc., Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited
Restricted access

Corresponding Author: Kirsten Stuber, MSN, MBA, FNP-BC, AOCNP